Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer von Petrylak, Daniel P., Kantoff, Philip, Vogelzang, Nicholas J., Mega, Anthony, Fleming, Mark T., Stephenson, Joe J., Frank, Richard, Shore, Neal D., Dreicer, Robert, McClay, Edward F., Berry, William R., Agarwal, Manish, DiPippo, Vincent A., Rotshteyn, Yakov, Stambler, Nancy, Olson, William C., Morris, Stephen A., Israel, Robert J.

Volltext

Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma von Siefker-Radtke, Arlene O., Necchi, Andrea, Park, Se Hoon, García-Donas, Jesús, Huddart, Robert A., Burgess, Earle F., Fleming, Mark T., Rezazadeh Kalebasty, Arash, Mellado, Begoña, Varlamov, Sergei, Joshi, Monika, Duran, Ignacio, Tagawa, Scott T., Zakharia, Yousef, Qi, Keqin, Akapame, Sydney, Triantos, Spyros, O'Hagan, Anne, Loriot, Yohann

Volltext

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial von de Bono, Johann S, Mehra, Niven, Scagliotti, Giorgio V, Castro, Elena, Dorff, Tanya, Stirling, Adam, Stenzl, Arnulf, Fleming, Mark T, Higano, Celestia S, Saad, Fred, Buttigliero, Consuelo, van Oort, Inge M, Laird, A Douglas, Mata, Marielena, Chen, Hsiang-Chun, Healy, Cynthia G, Czibere, Akos, Fizazi, Karim

Volltext

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicent... von Rosenberg, Jonathan E, Dr, Hoffman-Censits, Jean, MD, Powles, Tom, Prof, van der Heijden, Michiel S, Prof, Balar, Arjun V, MD, Necchi, Andrea, MD, Dawson, Nancy, Prof, O'Donnell, Peter H, MD, Balmanoukian, Ani, MD, Loriot, Yohann, MD, Srinivas, Sandy, MD, Retz, Margitta M, Prof, Grivas, Petros, MD, Joseph, Richard W, MD, Galsky, Matthew D, MD, Fleming, Mark T, MD, Petrylak, Daniel P, Prof, Perez-Gracia, Jose Luis, MD, Burris, Howard A, MD, Castellano, Daniel, MD, Canil, Christina, MD, Bellmunt, Joaquim, MD, Bajorin, Dean, Prof, Nickles, Dorothee, PhD, Bourgon, Richard, PhD, Frampton, Garrett M, PhD, Cui, Na, PhD, Mariathasan, Sanjeev, PhD, Abidoye, Oyewale, MD, Fine, Gregg D, MD, Dreicer, Robert, Prof

Volltext

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer von Galsky, Matthew D., Mortazavi, Amir, Milowsky, Matthew, George, Saby, Gupta, Sumati, Fleming, Mark T., Dang, Long H., Geynisman, Daniel M., Walling, Radhika, Alter, Robert S., Kassar, Mohamad, Wang, Jue, Gupta, Shilpa, Davis, Nancy, Picus, Joel, Philips, George, Quinn, David, Haines, G. Kenneth, Hahn, Noah M., Zhao, Qianqian, Yu, Menggang, Pal, Sumanta K.

Volltext

Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients von Hurria, Arti, Fleming, Mark T, Baker, Sharyn D, Kelly, Wm Kevin, Cutchall, Katie, Panageas, Katherine, Caravelli, James, Yeung, Henry, Kris, Mark G, Gomez, Jorge, Miller, Vincent A, D'Andrea, Gabriella, Scher, Howard I, Norton, Larry, Hudis, Clifford

Volltext

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes von Galsky, Matthew D., Wang, Huan, Hahn, Noah M., Twardowski, Przemyslaw, Pal, Sumanta K., Albany, Costantine, Fleming, Mark T., Starodub, Alexander, Hauke, Ralph J., Yu, Menggang, Zhao, Qianqian, Sonpavde, Guru, Donovan, Michael J., Patel, Vaibhav G., Sfakianos, John P., Domingo-Domenech, Josep, Oh, William K., Akers, Nicholas, Losic, Bojan, Gnjatic, Sacha, Schadt, Eric E., Chen, Rong, Kim-Schulze, Seunghee, Bhardwaj, Nina, Uzilov, Andrew V.

Volltext

Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide von de Bono, Johann S., Fleming, Mark T., Wang, Judy S., Cathomas, Richard, Miralles, Manuel Selvi, Bothos, John, Hinrichs, Mary Jane, Zhang, Qu, He, Peng, Williams, Marna, Rosenbaum, Anton, Liang, Meina, Vashisht, Kapil, Cho, Song, Martinez, Pablo, Petrylak, Daniel P.

Volltext

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer von Sonpavde, Guru, M.D, Aparicio, Ana M., M.D, Zhan, Feng, Ph.D, North, Brittany, B.Sc, DeLaune, Robert, M.D, Garbo, Lawrence E., M.D, Rousey, Steven R., M.D, Weinstein, Ralph E., M.D, Xiao, Lianchun, M.S, Boehm, Kristi A., M.S, Asmar, Lina, Ph.D, Fleming, Mark T., M.D, Galsky, Matthew D., M.D, Berry, William R., M.D, Von Hoff, Daniel D., M.D

Volltext

PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label singl... von Petrylak, Daniel P., Vogelzang, Nicholas J., Chatta, Kamal, Fleming, Mark T., Smith, David C., Appleman, Leonard J., Hussain, Arif, Modiano, Manuel, Singh, Parminder, Tagawa, Scott T., Gore, Ira, McClay, Edward F., Mega, Anthony E., Sartor, A. Oliver, Somer, Bradley, Wadlow, Raymond, Shore, Neal D., Olson, William C., Stambler, Nancy, DiPippo, Vincent A., Israel, Robert J.

Volltext

Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial von Pal, Sumanta K., Grivas, Petros, Gupta, Shilpa, Dizman, Nazli, Zengin, Zeynep, Valderrama, Begona P., Rodriguez-Vida, Alejo, Roghmann, Florian, Sevillano Fernandez, Elena, Matin, Surena F., Loriot, Yohann, Sridhar, Srikala S., Sonpavde, Guru, Fleming, Mark T., Lerner, Seth P., Bellmunt, Joaquim, Master, Viraj, Tripathi, Abhishek, Davis, Kim, van Veenhuyzen, David, Weng, Richard, Daneshmand, Siamak

Volltext

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer von Zhang, Tian, Harrison, Michael R., O'Donnell, Peter H., Alva, Ajjai S., Hahn, Noah M., Appleman, Leonard J., Cetnar, Jeremy, Burke, John M., Fleming, Mark T., Milowsky, Matthew I., Mortazavi, Amir, Shore, Neal, Sonpavde, Guru P., Schmidt, Emmett V., Bitman, Bojena, Munugalavadla, Veerendra, Izumi, Raquel, Patel, Priti, Staats, Janet, Chan, Cliburn, Weinhold, Kent J., George, Daniel J.

Volltext

A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer von George, Daniel J., Halabi, Susan, Heath, Elisabeth I., Sartor, A. Oliver, Sonpavde, Guru P., Das, Devika, Bitting, Rhonda L., Berry, William, Healy, Patrick, Anand, Monika, Winters, Carol, Riggan, Colleen, Kephart, Julie, Wilder, Rhonda, Shobe, Kellie, Rasmussen, Julia, Milowsky, Matthew I., Fleming, Mark T., Bearden, James, Goodman, Michael, Zhang, Tian, Harrison, Michael R., McNamara, Megan, Zhang, Dadong, LaCroix, Bonnie L., Kittles, Rick A., Patierno, Brendon M., Sibley, Alexander B., Patierno, Steven R., Owzar, Kouros, Hyslop, Terry, Freedman, Jennifer A., Armstrong, Andrew J.

Volltext

Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial von Pal, Sumanta K, Somford, Diederik M, Grivas, Petros, Sridhar, Srikala S, Gupta, Shilpa, Bellmunt, Joaquim, Sonpavde, Guru, Fleming, Mark T, Lerner, Seth P, Loriot, Yohann, Hoffman-Censits, Jean, Valderrama, Begoña P, Andresen, Corina, Schnabel, Marco J, Cole, Suzanne, Daneshmand, Siamak

Volltext

Sequential Therapy in Metastatic Renal Cell Carcinoma von Hirsch, Bradford R, Burke, John M, Agrawal, Manish, Hauke, Ralph J, Hutson, Thomas E, Doshi, Gury, Fleming, Mark T, Vogelzang, Nicholas J

Volltext

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer von Gupta, Shilpa, Nordquist, Luke T., Fleming, Mark T., Berry, William R., Zhang, Jingsong, Ervin, Sharon L., Eisner, Joel R., Baskin-Bey, Edwina S., Shore, Neal D.

Volltext

Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer von Morris, Michael J, Rathkopf, Dana E, Novotny, William, Gibbons, Jacqueline A, Peterson, Amy C, Khondker, Zakaria, Ouatas, Taoufik, Scher, Howard I, Fleming, Mark T

Volltext

Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer von Westaby, Daniel, Viscuse, Paul V., Ravilla, Rahul, de la Maza, Maria de los Dolores Fenor, Hahn, Andrew, Sharp, Adam, de Bono, Johann, Aparicio, Ana, Fleming, Mark T.

Volltext

Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials von Scher, Howard I, Fleming, Mark T, Morris, Michael J, Heller, Glenn

Volltext

Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity von Hahn, Noah M., M.D, Knudsen, Beatrice S., M.D., Ph.D, Daneshmand, Siamak, M.D, Koch, Michael O., M.D, Bihrle, Richard, M.D, Foster, Richard S., M.D, Gardner, Thomas A., M.D, Cheng, Liang, M.D, Liu, Ziyue, Ph.D, Breen, Timothy, Ph.D, Fleming, Mark T., M.D, Lance, Raymond, M.D, Corless, Christopher L., M.D., Ph.D, Alva, Ajjai S., M.D, Shen, Steven S., M.D., Ph.D, Huang, Fangjin, M.S, Gertych, Arkadiusz, Ph.D, Gallick, Gary E., Ph.D, Mallick, Jayati, M.D, Ryan, Christopher, M.D, Galsky, Matthew D., M.D, Lerner, Seth P., M.D, Posadas, Edwin M., M.D, Sonpavde, Guru, M.D

Volltext